	Ixabepilone
Accelerator mass spectrometry
Anti-cancer agent
Mass balance
Epothilone
	mass balance study
dose
ixabepilone relative
total radioactivity
radioactivity
urine
ixabepilone
TRA
higher plasma TRA
Plasma ixabepilone concentrations
patient
high concentrations
recovery
low levels
AUC
pseudopharmacokinetic parameters
AMS
drug
long half-life
Accelerator Mass Spectrometry
terminal elimination phase
metabolic
typical radio-tracer study
maximal concentration
plasma
mass
sample
mobile phase
study
total volume
lower
present investigation
Figure
Table
administration
bile duct
pharmacokinetics
carbon
faecal excretion
normal
naturally
humans

